The Global Head And Neck Cancer Therapeutics Market size is expected to reach $2.5 billion by 2028, rising at a market growth of 12.3% CAGR during the forecast period.
The majority of malignancies that are jointly referred to as head and neck cancers begin in the squamous cells that cover the mucosal surfaces of the head and neck. These tumors are known as head and neck squamous cell carcinomas. Head and neck malignancies can also begin in the salivary glands, muscles, sinuses, or nerves in the head and neck, however, squamous cell carcinomas are noticeably more common.
Numerous malignancies of the head and neck are curable, especially if detected early. Although eradicating cancer is the major objective of therapy, maintaining the function of the surrounding nerves, organs, and tissues is equally crucial. When planning therapy, physicians examine how treatment may influence a patient's quality of life, including how the patient feels, looks, speaks, eats, and breathes.
Surgical intervention, radiation treatment, chemotherapy, targeted therapy, and immunotherapy are the primary cancer treatments. Surgical procedures or radiation therapy alone, or a mix of the two, may be included in the treatment plan. The behavior of a specific head-neck cancer relies on its origin place (the primary site).
For instance, tumors that develop in the vocal cords behave quite differently from those that begin in the backside of the tongue, which is just an inch or less away from the vocal cords. Squamous cell carcinoma, which comes from the cells that cover the interior of the nose, mouth, and throat, is the most prevalent kind of cancer of the head and neck.
The COVID-19 pandemic has significantly impacted the care of different types of Head and neck cancer patients, having a greater impact on older patients, individuals operated primarily surgically, and those with fewer comorbidities. These individuals may experience poorer oncological outcomes due to missing or delayed diagnosis. Due to the COVID-19 pandemic, several cancer tests have been delayed or rescheduled, leaving a substantial number of people without access to required healthcare treatments. This interruption to cancer screening programs may have substantial consequences for patients, medical professionals, and health systems.
Immunotherapy is an innovative treatment for cancer, including head and neck, lymphoma, melanoma, and non-small cell lung cancer. Some tumors respond well to conventional therapies such as chemotherapy. In other instances, immunotherapy is combined with conventional cancer therapies to increase the body's natural defenses against cancer. As part of its regular functionality, the immune system discovers and eliminates aberrant cells, so preventing or stifling the formation of several malignancies. Immune cells, for instance, are occasionally seen in and surrounding tumors.
Head and neck cancers are classified according to their location. These regions include the oral cavity, pharynx, larynx, paranasal sinuses, and nasal cavity, as well as the salivary glands. An increase in alcohol and cigarette intake is a key cause of head and neck cancer. An estimated 75% of head and neck cancers are caused by alcohol and cigarette intake. Cancer will be the top cause of mortality, accounting for over 10 million fatalities, or one in six deaths.
Cancer of the head and neck are frequently treated with a mix of radiation and chemotherapy treatment. The adverse effects include hair loss, speech impairment, and loss of natural voice. In addition, after undergoing cancer surgery, people have difficulty eating. Although hair loss is a frequent side effect of chemotherapy, it does not affect everyone. Individuals can ask their care provider whether it is likely a medication side effect.
Based on the Therapy Type, the Head and Neck Cancer Therapeutics Market is segmented into Chemotherapy, Immunotherapy, and Targeted Therapy. The immunotherapy segment acquired the highest revenue share in the head and neck therapeutics market in 2021. It is because immunotherapy make use of the immune system to treat cancer. Pembrolizumab, an anti-PD1 immunotherapy that targets cells with a deficiency in their capacity to repair DNA, may fall under this category.
On the basis of the Route of Administration, the Head and Neck Cancer Therapeutics Market is divided into Injectable and Oral. The oral segment garnered a substantial revenue share in the head and neck cancer therapeutics market in 2021. Due to the rising number of oral medicinal medicines used to treat patients with Head and neck cancer. It is anticipated that the successful conclusion of the study and subsequent launch will stimulate segment growth. Patients with cancer are also administered oral chemotherapy.
By Distribution Channel, the Head and Neck Cancer Therapeutics Market is classified into Retail and Specialty Pharmacies, Hospital Pharmacies, and Online Pharmacies. The retail and specialty pharmacies witnessed the highest segment revenue share in the head and neck cancer therapeutics market in 2021. It is because specialty pharmacies offer medications unavailable in conventional pharmacies, such as immunotherapy drugs. Providing these drugs through a specialty pharmacy guarantees their appropriate and secure delivery.
| Report Attribute | Details |
|---|---|
| Market size value in 2021 | USD 1.1 Billion |
| Market size forecast in 2028 | USD 2.5 Billion |
| Base Year | 2021 |
| Historical Period | 2018 to 2020 |
| Forecast Period | 2022 to 2028 |
| Revenue Growth Rate | CAGR of 12.3% from 2022 to 2028 |
| Number of Pages | 206 |
| Number of Tables | 339 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Therapy Type, Route of Administration, Distribution Channel, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Region-wise, the Head and Neck Cancer Therapeutics Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment registered the largest revenue share in the head and neck cancer therapeutics market in 2021. It is due to the government assistance for the expansion of the healthcare sector, attractive reimbursement rules, a high level of illness awareness, and easy access to high-quality healthcare facilities are among the factors that have contributed to the expansion of the regional market.
Free Valuable Insights: Global Head And Neck Cancer Therapeutics Market size to reach USD 2.5 Billion by 2028
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Bristol Myers Squibb Company, and Clinigen Group PLC.
By Therapy Type
By Route of Administration
By Distribution Channel
By Geography
The global Head And Neck Cancer Therapeutics Market size is expected to reach $2.5 billion by 2028.
Increasing Demand For Immunotherapy Treatment are driving the market in coming years, however, Associated Side Effects Of Chemotherapy restraints the growth of the market.
Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Bristol Myers Squibb Company, and Clinigen Group PLC.
The expected CAGR of the Head And Neck Cancer Therapeutics Market is 12.3% from 2022 to 2028.
The Injectable segment acquired maximum revenue share in the Global Head & Neck Cancer Therapeutics Market by Route of Administration in 2021 thereby, achieving a market value of $2.1 billion by 2028.
The North America market dominated the Global Head & Neck Cancer Therapeutics Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1 billion by 2028.
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
